-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Reviewing CorMedix (NYSE:CRMD) and ORIC Pharmaceuticals (NASDAQ:ORIC)
Reviewing CorMedix (NYSE:CRMD) and ORIC Pharmaceuticals (NASDAQ:ORIC)
CorMedix (NYSE:CRMD – Get Rating) and ORIC Pharmaceuticals (NASDAQ:ORIC – Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, valuation and profitability.
Profitability
This table compares CorMedix and ORIC Pharmaceuticals' net margins, return on equity and return on assets.
Get CorMedix alerts:| Net Margins | Return on Equity | Return on Assets | |
| CorMedix | -25,202.44% | -48.87% | -44.76% |
| ORIC Pharmaceuticals | N/A | -32.11% | -29.50% |
Volatility and Risk
CorMedix has a beta of 2.2, meaning that its stock price is 120% more volatile than the S&P 500. Comparatively, ORIC Pharmaceuticals has a beta of 1.05, meaning that its stock price is 5% more volatile than the S&P 500.
Institutional & Insider Ownership
33.8% of CorMedix shares are owned by institutional investors. Comparatively, 89.7% of ORIC Pharmaceuticals shares are owned by institutional investors. 2.8% of CorMedix shares are owned by insiders. Comparatively, 6.2% of ORIC Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.Valuation and Earnings
This table compares CorMedix and ORIC Pharmaceuticals' revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| CorMedix | $190,000.00 | 846.00 | -$28.21 million | ($0.79) | -4.95 |
| ORIC Pharmaceuticals | N/A | N/A | -$78.71 million | ($2.15) | -2.06 |
CorMedix has higher revenue and earnings than ORIC Pharmaceuticals. CorMedix is trading at a lower price-to-earnings ratio than ORIC Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of recent ratings for CorMedix and ORIC Pharmaceuticals, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| CorMedix | 0 | 0 | 0 | 0 | N/A |
| ORIC Pharmaceuticals | 0 | 3 | 2 | 0 | 2.40 |
ORIC Pharmaceuticals has a consensus target price of $22.00, suggesting a potential upside of 397.74%. Given ORIC Pharmaceuticals' higher possible upside, analysts plainly believe ORIC Pharmaceuticals is more favorable than CorMedix.
Summary
ORIC Pharmaceuticals beats CorMedix on 8 of the 12 factors compared between the two stocks.
About CorMedix
(Get Rating)
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
About ORIC Pharmaceuticals
(Get Rating)
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. It has a license and collaboration agreement with Voronoi Inc.; and a license agreement with Mirati Therapeutics, Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
Receive News & Ratings for CorMedix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CorMedix and related companies with MarketBeat.com's FREE daily email newsletter.
CorMedix (NYSE:CRMD – Get Rating) and ORIC Pharmaceuticals (NASDAQ:ORIC – Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, valuation and profitability.
CorMedex(紐約證券交易所代碼：CRMD-GET)和ORIC PharmPharmticals(納斯達克：ORIC-GET評級)都是小盤醫療公司，但哪隻股票更好？我們將根據兩家公司的風險實力、分析師建議、股息、機構所有權、收益、估值和盈利能力對它們進行比較。
Profitability
盈利能力
This table compares CorMedix and ORIC Pharmaceuticals' net margins, return on equity and return on assets.
此表比較了CorMedex和ORIC製藥公司的淨利潤率、股本回報率和資產回報率。
| Net Margins | Return on Equity | Return on Assets | |
| CorMedix | -25,202.44% | -48.87% | -44.76% |
| ORIC Pharmaceuticals | N/A | -32.11% | -29.50% |
| 淨利潤率 | 股本回報率 | 資產回報率 | |
| CorMedex | -25,202.44% | -48.87% | -44.76% |
| 奧瑞克製藥公司 | 不適用 | -32.11% | -29.50% |
Volatility and Risk
波動性和風險
CorMedix has a beta of 2.2, meaning that its stock price is 120% more volatile than the S&P 500. Comparatively, ORIC Pharmaceuticals has a beta of 1.05, meaning that its stock price is 5% more volatile than the S&P 500.
CorMedex的貝塔係數為2.2，這意味着其股價的波動性比標準普爾500指數高120%。相比之下，ORIC PharmPharmticals的貝塔係數為1.05，這意味着其股價的波動性比標準普爾500指數高5%。
Institutional & Insider Ownership
機構與內部人持股
Valuation and Earnings
估值和收益
This table compares CorMedix and ORIC Pharmaceuticals' revenue, earnings per share (EPS) and valuation.
該表格比較了CorMedex和ORIC PharmPharmticals的收入、每股收益(EPS)和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| CorMedix | $190,000.00 | 846.00 | -$28.21 million | ($0.79) | -4.95 |
| ORIC Pharmaceuticals | N/A | N/A | -$78.71 million | ($2.15) | -2.06 |
| 總收入 | 價格/銷售額比 | 淨收入 | 每股收益 | 市盈率 | |
| CorMedex | $190,000.00 | 846.00 | -2,821萬元 | ($0.79) | -4.95 |
| 奧瑞克製藥公司 | 不適用 | 不適用 | -7,871萬元 | ($2.15) | -2.06 |
CorMedix has higher revenue and earnings than ORIC Pharmaceuticals. CorMedix is trading at a lower price-to-earnings ratio than ORIC Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
CorMedex的收入和收益高於ORIC製藥公司。CorMedex的市盈率低於ORIC PharmPharmticals，表明它目前是兩隻股票中更負擔得起的一隻。
Analyst Ratings
分析師評級
This is a breakdown of recent ratings for CorMedix and ORIC Pharmaceuticals, as provided by MarketBeat.com.
這是MarketBeat.com提供的CorMedex和ORIC製藥公司最近的評級細目。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| CorMedix | 0 | 0 | 0 | 0 | N/A |
| ORIC Pharmaceuticals | 0 | 3 | 2 | 0 | 2.40 |
| 銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
| CorMedex | 0 | 0 | 0 | 0 | 不適用 |
| 奧瑞克製藥公司 | 0 | 3 | 2 | 0 | 2.40 |
ORIC Pharmaceuticals has a consensus target price of $22.00, suggesting a potential upside of 397.74%. Given ORIC Pharmaceuticals' higher possible upside, analysts plainly believe ORIC Pharmaceuticals is more favorable than CorMedix.
Oric PharmPharmticals的共識目標價為2200美元，暗示潛在上漲397.74%。考慮到ORIC製藥更有可能上行，分析師顯然認為ORIC製藥比CorMedex更有利。
Summary
摘要
ORIC Pharmaceuticals beats CorMedix on 8 of the 12 factors compared between the two stocks.
在比較兩隻股票的12個因素中，Oric PharmPharmticals有8個超過CorMedex。
About CorMedix
關於CorMedex
(Get Rating)
(獲取評級)
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
CorMedex公司是一家生物製藥公司，專注於在美國和國際上開發和商業化用於預防和治療傳染病和炎症性疾病的治療產品。它的主要候選產品是DefenCath/Neutrolin，這是一種新型的抗感染解決方案，用於減少和預防臨牀環境中需要中心靜脈導管的患者的導管相關感染和血栓形成，如血液透析、完全腸外營養和腫瘤學。該公司前身為Picton Holding Company，Inc.，於2007年1月更名為CorMedex，Inc.。CorMedex Inc.成立於2006年，總部設在新澤西州的伯克利高地。
About ORIC Pharmaceuticals
ORIC製藥公司簡介
(Get Rating)
(獲取評級)
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. It has a license and collaboration agreement with Voronoi Inc.; and a license agreement with Mirati Therapeutics, Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
奧瑞克製藥公司是一家臨牀階段的生物製藥公司，在美國發現和開發治療癌症的療法。其臨牀階段的候選產品包括正在開發的CD73口服生物可用小分子抑制劑ORIC-533，用於耐受化療和免疫治療的治療方案；ORIC-944，用於前列腺癌的多梳抑制複合體2的變構抑制劑；以及ORIC-114，一種腦穿透性口服生物可用不可逆抑制劑，旨在選擇性地靶向表皮生長因子受體和人表皮生長因子受體2，對外顯子20插入突變具有高效力。該公司還在開發針對其他癌症耐藥機制的多個發現階段的精確藥物。它與Voronoi Inc.簽訂了許可和合作協議；與Mirati Treateutics，Inc.簽訂了許可協議。該公司成立於2014年，總部位於加利福尼亞州舊金山南部。
Receive News & Ratings for CorMedix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CorMedix and related companies with MarketBeat.com's FREE daily email newsletter.
接受CorMedex Daily的新聞和評級-在下面輸入您的電子郵件地址，以通過MarketBeat.com的免費每日電子郵件時事通訊接收對CorMedex和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧